Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | C120 - Multiple Sclerosis Disease-modifying Treatment

Wednesday 04/06/22
07:00 AM - 09:00 AM PDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Jacqueline Bernard, MD, FAAN
Multiple Sclerosis
Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and the impact of COVID-19 disease and vaccination on DMT doses.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student
Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 09:00 AM PDT Speaker Multiple Sclerosis Disease-modifying Treatment
Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD
07:00 AM - 07:00 AM PDT Speaker Walk-in Slides
Jacqueline Bernard, MD, FAAN
Faculty Disclosures
Jacqueline Bernard, MD, FAAN Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD Dr. Lane has nothing to disclose.